CN108498855A - A kind of antibacterial anti hemorrhagic colloidal sol and preparation method thereof - Google Patents
A kind of antibacterial anti hemorrhagic colloidal sol and preparation method thereof Download PDFInfo
- Publication number
- CN108498855A CN108498855A CN201810439740.3A CN201810439740A CN108498855A CN 108498855 A CN108498855 A CN 108498855A CN 201810439740 A CN201810439740 A CN 201810439740A CN 108498855 A CN108498855 A CN 108498855A
- Authority
- CN
- China
- Prior art keywords
- carboxymethyl chitosan
- colloidal sol
- aqueous solution
- content
- sodium alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/224—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials containing metals, e.g. porphyrins, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention discloses a kind of antibacterial anti hemorrhagic colloidal sols and preparation method thereof, are made of raw material of sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, water soluble metal phthalocyanine, glucose and water for injection.Antibacterial anti hemorrhagic colloidal sol of the present invention also has and irrigates and anti-infectious function, and be suitable for irregular wound other than good haemostatic effect；And it can avoid traditional hemostatic material（Hemostatic gauze, styptic powder, styptic sponge etc.）Bioadhesion is strong, the problem of easily causing secondary bleeding because of removal, and further can generate significant antibacterial effect under natural light irradiation indoors, and depth solves the problems, such as wound infection.
Description
Technical field
The invention belongs to antibacterial anti hemorrhagic field of material technology, stop more particularly to a kind of antibacterial based on marine polysaccharide
Blood colloidal sol and its preparation method and application.
Background technology
Traumatic hemorrhage is one of common condition of the injury in battlefield and all kinds of scenes of the accident, and bleeding is out of control to cause wounded scene dead
First cause.Even if the wounded can send to hospital and rescue, massive blood loss can cause the later stage higher death rate and complication before institute（Such as
Amputation etc.）, therefore, it control effectively to live wounded's bleeding significant.On the other hand, in various surgical operations, subtract
Few bleeding, shortens operating time, plays an important roll for patient's prognosis.Traditional hemostasis equipment and hemostatic material（Veil stretches tight
Band）For many positions of human body（Such as chest, abdomen, head, neck）Can not use or ineffective, and for irregular shape, depth,
The haemostatic effect of the common live wound such as narrow and operative incision is very undesirable.And Fibrin Glue, gelfoam, oxidized fibre
Although the material of the absorbable hemostatics such as element, microfibrillar collagen, Fibrin Glue and alginic acid fibre is answered in clinic
With, but there is also many deficiencies, and mainly hemostasis efficiency is still to be improved, and has a single function.Therefore, exploitation, which has, is not easy because applying
The advantages that material removes and causes secondary insult, and the novel hemostatic material for having both the functions such as quick-acting haemostatic powder, flushing, antibacterial is current
The hot and difficult issue of research and development.
Situ-gel is after one kind is administered with liquid condition, can be changed into semisolid from liquid condition immediately in application site
The gel rubber material of gel state.Situ-gel is as ideal biological support, can be thin because it is similar to natural extracellular matrix
Born of the same parents and biomolecule provide suitable microenvironment, and porous structure can effective dispersing small molecules；In addition, it is with good biology
Compatibility, biological degradability, invasiveness is small, is applicable to the wound of various irregular shapes, as three Wikis rich in moisture
Matter attracts wide public concern in terms of hemostasis.
Sodium alginate be it is a kind of byβD-MANNOSE aldehydic acid（β- D-mannuronic, M）Withα- L- guluronic acids（α-L-
Guluronic, G）It presses（1→4）Water soluble polymer natural polysaccharide made of key connection, in aqueous solution or high humidity environment
In can dissolve rapidly.- COOH on sodium alginate macromolecular chain is reacted with the NaCl in blood, can break the ionization equilibrium of blood
And activate coagulation factor；And in coagulation process, sodium alginate can largely absorb the moisture in blood, make the concentration of blood and stick
Degree increases, flows decrease, meanwhile, the lysigenous viscoid of sodium alginate blocks capillary end, and meeting blood platelet can be rapid
It adheres to, to play the effect of hemostasis.In addition, sodium alginate also has humectant, antibacterial and bactericidal property, Neng Gouzuo
Used for medical dressing, alginate medical dressing can not only absorbing wound exudate, and can be formed in wound surface
Gel mould provides suitable wetting physiology microenvironment for wound surface healing, while reducing the bacterium infection of wound site.
Carboxymethyl chitosan is a kind of amphoteric polysaccharide, is existed in the form of ampholytes in aqueous solution, contained ammonia
Base can protonate generation cation, and carboxyl can ionize out anion, can increase the aggregation of red blood cell and the adherency of blood platelet, from
And accelerate hemostasis, shorten the clotting time.And the cation effect on carboxymethyl chitosan quaternary ammonium salt can promote red blood cell poly-
Collection, to play anastalsis；And quaternary ammonium root cation can also inhibit microorganism by destroying the cytoplasma membrane of microorganism
Growth.In addition, carboxymethyl chitosan and carboxymethyl chitosan quaternary ammonium salt have stronger water absorbing capacity, and with extraordinary viscous
Attached property, can securely be pasted at the surface of a wound, fill wound.
In addition, after hemostasis is achieved, preventing bacterium infection also particularly significant for the healing of wound.Photosensitizer is that one kind can
It absorbs photon and generates excitation electronics, the electronics in excitation state again causes excessive energy transfer to oxygen molecule a series of
Photochemically reactive substance.Photosensitizer of the phthalocyanine as the second generation is a kind of 18 π with height conjugation-The plane virtue of electronics
The big ring substance of fragrance.In antibiosis, photosensitizer is enriched in first in microbial cell and/or on cell wall, in appropriate wave
Long light irradiation and the participation of oxygen issue third contact of a total solar or lunar eclipse chemical reaction, generate active oxygen, and active oxygen in different ways causes cell
Oxidative damage achievees the effect that antibacterial.In addition, phthalocyanine also has small toxicity, sterilization speed fast, and natural light irradiation indoors
A variety of advantages of antibacterial effect can be generated down.
To sum up, although conventional solid hemostatic material bioadhesion is strong, haemostatic effect is good, have a single function, nothing
Method is rinsed wound, and easily causes secondary insult in removal.Although liquid hemostatic material has pre-washing function, operation letter
Just it, is applicable to irregular wound, but tissue adhension intensity is insufficient, haemostatic effect is bad.And although situ-gel compensates for admittedly
The deficiency of both body hemostatic material and liquid hemostatic material part, but after situ-gel is changed into semi-solid gel from liquid
Just lose pre-washing function.The present invention imitates the formation mechenism of situ-gel, is retaining outside the original advantage of situ-gel, is passing through
It is changed into the colloidal sol for having mobility by liquid after so that each component is mixed, assigns the function of hemostatic material flushing.And it is each in colloidal sol
Macromolecular components（Sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt）All there is antibacterial activity, lead between them
It crosses hydrogen bond and a small amount of ionic bond forms dimensional network structure, solve the problems, such as postoperative wound infection.In addition, the phthalocyanine in colloidal sol
Antibacterial functions can be further played under natural light irradiation indoors.
Invention content
In order to solve, liquid hemostatic material haemostatic effect currently on the market is bad, solid hemostatic material has a single function and deposits
The wound infection the problem of, the present invention provides a kind of antibacterial anti hemorrhagic colloidal sols and preparation method thereof.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of photosensitive antibacterial anti hemorrhagic colloidal sol is by sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, water-soluble
Property phthalocyanine, glucose and water for injection are made of raw material；Wherein, the content of sodium alginate is 0.1-10g/L, carboxymethyl chitosan
Content be 0.5-50g/L, the content of carboxymethyl chitosan quaternary ammonium salt is 0-20g/L, the content of water soluble metal phthalocyanine is 0-0.1g/
L, the content of glucose is 0-450 g/L.
The water soluble metal phthalocyanine includes chow ring or is axially connected with amino, carboxyl, sulfonic group, quaternary ammonium group, PEG chains etc.
Phthalocyanine compound and its esters.
The preparation method of the antibacterial anti hemorrhagic colloidal sol includes the following steps：
1）Sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, water soluble metal phthalocyanine and glucose are respectively placed in close
It closes in automatic stirring container, water for injection is added, at room temperature closed low speed（≤600rpm）1-2h is stirred, alginic acid is respectively obtained
Sodium water solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, phthalocyanine aqueous solution and glucose are water-soluble
Liquid, filtering with microporous membrane degerming are for use；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, phthalocyanine water
Solution and glucose solution mix in closed automatic stirring container in proportion, and concussion stirring 5-10min, filling at room temperature,
Up to the antibacterial anti hemorrhagic colloidal sol.
Beneficial effects of the present invention and outstanding advantage are：
1）The present invention imitates situ-gel formation mechenism, and colloidal sol obtained is ensureing outside good haemostatic effect also have and facilitate wound
The characteristics of face is rinsed is suitable for the not easy-operating Wound treatment such as in irregular shape, deep, narrow.
2）The present invention makes sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt by simple physical mixed
While these three polymer keep respective molecular structure, make between them to be formed by hydrogen bond and a small amount of ionic bond fine and close vertical
Volume grid structure blocks the surface of a wound to reach good, assists the effect of hemostasis.Simultaneously as what is wherein contained is a large amount of hydrophilic
Group makes product have high-hygroscopicity, can promptly absorb the blood in the surface of a wound.
3）In addition to sodium alginate and chitosan derivative beyond the region of objective existence with good anti-microbial property in colloidal sol prepared by the present invention, also
It is embedded in phthalocyanine in its three-dimensional network gel structure, better antibacterial effect can be played under natural light irradiation indoors, from
And further it effectively prevent wound infection.
Specific implementation mode
In order to make content of the present invention easily facilitate understanding, With reference to embodiment to of the present invention
Technical solution is described further, but the present invention is not limited only to this.
Embodiment 1
1）By sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, tetracarboxylic acid phenoxyl Phthalocyanine Zinc and grape sugar
It is not placed in closed automatic stirring container, water for injection is added, at room temperature closed low speed（≤600rpm）1h is stirred, is respectively obtained
Carboxymethyl chitosan sugar aqueous solution that sodium alginate aqueous solution that content is 2.1g/L, content are 10.7g/L, content 10.7g/L
Carboxymethyl chitosan quaternary ammonium salt aqueous solution, content be 0.29g/L tetracarboxylic acid phenoxyl Phthalocyanine Zinc aqueous solution and content be
The glucose solution of 960g/L, it is for use through filtering with microporous membrane degerming respectively；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, tetracarboxylic
Phenoxy group Phthalocyanine Zinc aqueous solution and glucose solution by volume 20:30:10:1:3 mix in closed automatic stirring container,
At room temperature oscillation stirring 6min, so as to get colloidal sol in sodium alginate content be 0.67g/L, the content of carboxymethyl chitosan is
5 g/L, carboxymethyl chitosan quaternary ammonium salt content be 1.67 g/L, the content of tetracarboxylic acid phenoxyl Phthalocyanine Zinc be 0.0045g/L,
The content of glucose is 45 g/L, filling to get the antibacterial anti hemorrhagic colloidal sol.
Embodiment 2
1）By sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zincs and Portugal
Grape sugar is respectively placed in closed automatic stirring container, water for injection is added, at room temperature closed low speed（≤600rpm）2h is stirred, point
Not obtaining carboxymethyl chitosan sugar aqueous solution, content that sodium alginate aqueous solution, content that content is 2.1g/L are 10.7g/L is
The water of the carboxymethyl chitosan quaternary ammonium salt aqueous solution of 10.7g/L, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zinc that content is 0.45g/L
Solution and the glucose solution that content is 960g/L, it is for use through filtering with microporous membrane degerming respectively；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, 1- (4-
Aminoethyl phenoxy group) Phthalocyanine Zinc aqueous solution and glucose solution by volume 20:30:10:1:3 in closed automatic stirring container
Middle mixing, at room temperature oscillation stirring 6min, so as to get colloidal sol in sodium alginate content be 0.67g/L, carboxymethyl chitosan
It is 5 g/L, the content that the content of carboxymethyl chitosan quaternary ammonium salt is 1.67 g/L, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zinc is
0.007g/L, glucose content be 45 g/L, it is filling to get the antibacterial anti hemorrhagic colloidal sol.
Embodiment 3
1）By sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, tetracarboxylic acid phenoxyl Phthalocyanine Zinc and grape sugar
It is not placed in closed automatic stirring container, water for injection is added, at room temperature closed low speed（≤600rpm）2h is stirred, is respectively obtained
Carboxymethyl chitosan sugar aqueous solution that sodium alginate aqueous solution that content is 2.2g/L, content are 10.8g/L, content 10.8g/L
Carboxymethyl chitosan quaternary ammonium salt aqueous solution, content be 0.43g/L tetracarboxylic acid phenoxyl Phthalocyanine Zinc aqueous solution and content be
The glucose solution of 968g/L, it is for use through filtering with microporous membrane degerming respectively；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, tetracarboxylic
Phenoxy group Phthalocyanine Zinc aqueous solution and glucose solution by volume 40:60:20:3:6 mix in closed automatic stirring container,
At room temperature oscillation stirring 6min, so as to get colloidal sol in sodium alginate content be 0.67g/L, the content of carboxymethyl chitosan is
5 g/L, carboxymethyl chitosan quaternary ammonium salt content be 1.67 g/L, the content of tetracarboxylic acid phenoxyl Phthalocyanine Zinc is 0.0068 g/
L, the content of glucose is 45 g/L, filling to get the antibacterial anti hemorrhagic colloidal sol.
Embodiment 4
1）By sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zincs and Portugal
Grape sugar is respectively placed in closed automatic stirring container, water for injection is added, at room temperature closed low speed（≤600rpm）2h is stirred, point
Not obtaining carboxymethyl chitosan sugar aqueous solution, content that sodium alginate aqueous solution, content that content is 2.2g/L are 10.8g/L is
The carboxymethyl chitosan quaternary ammonium salt aqueous solution of 10.8g/L, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zinc that content is 0.67g/L are water-soluble
Liquid and the glucose solution that content is 968g/L, it is for use through filtering with microporous membrane degerming respectively；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, 1- (4-
Aminoethyl phenoxy group) Phthalocyanine Zinc aqueous solution and glucose solution by volume 40:60:20:3:6 in closed automatic stirring container
Middle mixing, at room temperature oscillation stirring 6min, so as to get colloidal sol in sodium alginate content be 0.67g/L, carboxymethyl chitosan
Content be 5 g/L, the content of carboxymethyl chitosan quaternary ammonium salt is that 1.67 g/L, 1- (4- aminoethyls phenoxy group) Phthalocyanine Zinc contains
Amount is 0.011 g/L, the content of glucose is 45 g/L, filling to get the antibacterial anti hemorrhagic colloidal sol.
Embodiment 5
1）Sodium alginate, carboxymethyl chitosan, tetracarboxylic acid phenoxyl Phthalocyanine Zinc and glucose are respectively placed in closed automatic stirring
In container, water for injection is added, at room temperature closed low speed（≤600rpm）2h is stirred, the seaweed that content is 2.1g/L is respectively obtained
The tetracarboxylic acid phenoxyl phthalocyanine that carboxymethyl chitosan sugar aqueous solution that acid sodium aqueous solution, content are 10.7g/L, content are 0.29g/L
Zinc aqueous solution and content are 960g/L glucose solutions, for use through filtering with microporous membrane degerming respectively；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, tetracarboxylic acid phenoxyl Phthalocyanine Zinc aqueous solution and grape
Sugar aqueous solution by volume 30:30:1:3 mix in closed automatic stirring container, at room temperature oscillation stirring 6min, so as to get
The content of sodium alginate is 1g/L in colloidal sol, the content of carboxymethyl chitosan is 5 g/L, the content of tetracarboxylic acid phenoxyl Phthalocyanine Zinc
Content for 0.0045g/L, glucose is 45 g/L, filling to get the antibacterial anti hemorrhagic colloidal sol.
6 mouse tail wound hemostasis of embodiment is tested
Experimental group：Antibacterial anti hemorrhagic colloidal sol prepared by embodiment 1.
Control group：Respectively as a contrast with 0.9% physiological saline, certain commercially available brand fluid haemostatic membrane.
Method：Experiment healthy adult female mice totally 18, weight are 25 ± 2g, are randomly divided into 0.9% physiological saline
Group, commercially available fluid haemostatic membrane group and antibacterial anti hemorrhagic colloidal sol group, are numbered respectively by every group 6；Use chloraldurate（7%）Intraperitoneal injection
Anesthesia places it in fixator after anaesthetizing successfully and cut tail experiment, to compare the bleeding stopping period of three groups of mouse.Cut tail length degree
About 2cm, it is slight to oppress, the tail portion bled is immersed in testing sample solution, timing is started, every 10s quick-replaceable solution,
Until timing terminates when mouse tail stopping is bled.The time of record hemostasis starting and termination, bleeding stopping period is calculated to obtain, as a result such as table
Shown in 1.
1 mouse tail wound hemostasis of table tests bleeding stopping period
By table 1 as it can be seen that the average bleeding stopping period of commercially available fluid haemostatic membrane group is respectively than 0.9% physiological saline group shortening about 25%, and
The average bleeding stopping period of antibacterial anti hemorrhagic colloidal sol group shortens about 50% than commercially available fluid haemostatic membrane group, significant difference（P<0.01）, card
The haemostatic effect of bright antibacterial anti hemorrhagic colloidal sol provided by the invention is better than commercially available fluid haemostatic membrane.
7 rabbit back wound hemostasis experiments of embodiment
Experimental group：Antibacterial anti hemorrhagic colloidal sol prepared by embodiment 1.
Control group：Respectively as a contrast with 0.9% physiological saline, certain commercially available brand fluid haemostatic membrane.
Method：Experiment healthy adult Female rabbits 6,2 ± 0.2kg of weight.The experimental implementation of control group and experimental group
It is completed based on an animal body.It is slowly injected in rabbit auricular vein using Su Mian Xin, is placed it in fixator after anaesthetizing successfully
Wound hemostasis experiment is carried out to compare three groups of bleeding stopping period.Back part of animal is lost hair or feathers and uses 95% alcohol disinfecting, along backbone both sides
Symmetry respectively cuts 6 circular incisions, and diameter about 1.0cm, depth is first to skin ring layer, and then carefully separation is avoided to fascia layer
Big blood vessel in subcutaneous tissue.Slightly oppresses and record bleeding initial time（End time is that wound stops the oozing of blood moment）, experiment
In the process every the 10 seconds blood with cotton wiping wound perimeter exudation, to observe.The hemostasis experimentation phase of six rabbit
Together, the results are shown in Table 2.
2 rabbit back wound hemostasis experiment bleeding stopping periods of table compare
As can be seen from Table 2, the average bleeding stopping period of commercially available fluid haemostatic membrane group shortens 22% than 0.9% physiological saline group；Antibacterial anti hemorrhagic
The average bleeding stopping period of colloidal sol group shortens 68% than commercially available fluid haemostatic membrane group, significant difference（P<0.01）.This is fully demonstrated
The haemostatic effect of antibacterial anti hemorrhagic colloidal sol prepared by the present invention is substantially better than commercially available fluid haemostatic membrane.
8 rabbit back wound hemostasis experiments of embodiment
Experimental group：Antibacterial anti hemorrhagic colloidal sol prepared by embodiment 5.
Control group：Respectively as a contrast with 0.9% physiological saline, certain commercially available brand fluid haemostatic membrane.
Method：Experiment healthy adult Female rabbits 6,2 ± 0.2kg of weight.The experimental implementation of control group and experimental group
It is completed based on an animal body.It is slowly injected in rabbit auricular vein using Su Mian Xin, is placed it in fixator after anaesthetizing successfully
Wound hemostasis experiment is carried out to compare three groups of bleeding stopping period.Back part of animal is lost hair or feathers and uses 95% alcohol disinfecting, along backbone both sides
Symmetry respectively cuts 6 circular incisions, and diameter about 1.0cm, depth is first to skin ring layer, and then carefully separation is avoided to fascia layer
Big blood vessel in subcutaneous tissue.Slightly oppresses and record bleeding initial time（End time is that wound stops the oozing of blood moment）, experiment
In the process every the 10 seconds blood with cotton wiping wound perimeter exudation, to observe.The hemostasis experimentation phase of six rabbit
Together, the results are shown in Table 3.
3 rabbit back wound hemostasis experiment bleeding stopping periods of table compare
By table 3 as it can be seen that the average bleeding stopping period of commercially available fluid haemostatic membrane group shortens 22% than 0.9% physiological saline group；Antibacterial anti hemorrhagic
The average bleeding stopping period of colloidal sol group shortens 68% than commercially available fluid haemostatic membrane group, significant difference（P<0.01）.This is fully demonstrated
The haemostatic effect of antibacterial anti hemorrhagic colloidal sol prepared by the present invention is substantially better than commercially available fluid haemostatic membrane.
9 antibacterial experiment of embodiment
Experimental group：Antibacterial anti hemorrhagic colloidal sol prepared by embodiment 1-4（Antibacterial anti hemorrhagic colloidal sol group（Add phthalocyanine））.
Control group：Respectively with PBS buffer solution, the simple phthalocyanine of various concentration and the carboxymethyl chitosan, the carboxylic that do not add phthalocyanine
Colloidal sol is blended in methyl chitosan quaternary ammonium salt and sodium alginate（Colloidal sol group（Not plus phthalocyanine））As a control group.
Experimental group is both needed to carry out phototoxicity with control group and dark toxicity is tested.
Method：The Staphylococcus aureus of the suitable size of picking from activated Luria-Bertain high salt culture mediums
Then appropriate PBS is added in beaker in bacterium bacterium colony, ultrasonic 5min makes it become uniform bacteria suspension, takes a small amount of bacteria suspension in blood
In ball count plate, make the control of its bacteria suspension concentration in 2-5 × 106CFU/mL.The bacteria suspension prepared is added with 100 μ L of every hole
Into sterile 96 orifice plate, then the testing sample solution of Fresh is added in corresponding orifice plate so that testing sample solution
Volume is to be blown and beaten using liquid-transfering gun uniform per 100 μ L of hole.Prepared drug sensitive plate is placed in 37 DEG C of incubators and is protected from light culture
6 hours make thalline that drug is fully absorbed and be adsorbed, are then measured to the bacteriostasis rate under dark condition.Light is prepared again
Toxicity drug sensitive plate uses the feux rouges of >=610nm（15mW/cm2）30min is irradiated, then the bacteriostasis rate under illumination condition is carried out
It measures.The results are shown in Table 4.Every group of experiment at least repeats three times.
Bacteriostasis rate computational methods：Bacteriostasis rate=100% ×（1- experimental groups clump count average value/control group clump count average value）
Table 4 is directed to the bacteriostasis rate of staphylococcus aureus
As shown in Table 4, do not add the colloidal sol group of phthalocyanine to have certain fungistatic effect, but the antibacterial anti hemorrhagic colloidal sol after phthalocyanine is added through light
It is significantly improved according to rear bacteriostasis, and higher than the bacteriostasis under simple phthalocyanine illumination.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification should all belong to the covering scope of the present invention.
Claims (5)
1. a kind of antibacterial anti hemorrhagic colloidal sol, it is characterised in that：By sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium
Salt, water soluble metal phthalocyanine, glucose and water for injection are made of raw material；Wherein, the content of sodium alginate is 0.1-10g/L, carboxylic first
The content of base enclosure glycan is 0.5-50g/L, the content of carboxymethyl chitosan quaternary ammonium salt is 0-20g/L, the content of water soluble metal phthalocyanine
Content for 0-0.1g/L, glucose is 0-450 g/L.
2. a kind of preparation method of antibacterial anti hemorrhagic colloidal sol as described in claim 1, it is characterised in that：Include the following steps：
1）It is separately added into sodium alginate, carboxymethyl chitosan, carboxymethyl chitosan quaternary ammonium salt, water soluble metal phthalocyanine and glucose
Water for injection, closed stirring at low speed 1-2h, obtains sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl at room temperature
Chitosan quaternary ammonium saline solution, phthalocyanine aqueous solution and glucose solution, filtering with microporous membrane degerming are for use；
2）By gained sodium alginate aqueous solution, carboxymethyl chitosan sugar aqueous solution, carboxymethyl chitosan quaternary ammonium salt aqueous solution, phthalocyanine water
Solution and glucose solution mix in closed automatic stirring container in proportion, and concussion stirring 5-10min, then fills at room temperature
Dress is to get the antibacterial anti hemorrhagic colloidal sol.
3. the preparation method of antibacterial anti hemorrhagic colloidal sol according to claim 2, it is characterised in that：Step 1）Stirring at low speed turns
Speed is≤600rpm.
4. a kind of antibacterial anti hemorrhagic colloidal sol as described in claim 1 is as the application in anti-biotic material.
5. a kind of antibacterial anti hemorrhagic colloidal sol as described in claim 1 is as the application in hemostatic material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810439740.3A CN108498855B (en) | 2018-05-09 | 2018-05-09 | Antibacterial hemostatic sol and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810439740.3A CN108498855B (en) | 2018-05-09 | 2018-05-09 | Antibacterial hemostatic sol and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108498855A true CN108498855A (en) | 2018-09-07 |
| CN108498855B CN108498855B (en) | 2021-04-27 |
Family
ID=63400129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810439740.3A Active CN108498855B (en) | 2018-05-09 | 2018-05-09 | Antibacterial hemostatic sol and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108498855B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109680498A (en) * | 2019-01-11 | 2019-04-26 | 深圳市科能医疗器械有限公司 | A kind of medical preparation method for resisting antibacterial gauze of nanometer-level silver ion |
| CN111533827A (en) * | 2020-06-15 | 2020-08-14 | 北京化工大学 | Electronegative polysaccharide quaternary ammonium salt hemostatic material and preparation method and application thereof |
| CN113855844A (en) * | 2021-09-18 | 2021-12-31 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Antibacterial material and preparation method and application thereof |
| CN115591008A (en) * | 2021-12-31 | 2023-01-13 | 上海炫鑫医药科技有限公司（Cn） | Spray-type liquid wound-protecting dressing and preparation method thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001029384A (en) * | 1999-05-20 | 2001-02-06 | Kao Corp | Absorptive article |
| WO2002090361A1 (en) * | 2001-03-21 | 2002-11-14 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| CN1593424A (en) * | 2004-07-15 | 2005-03-16 | 福州大学 | Novel method for preparing anticancer photosensitizer of amphiphilic phthalocyanine and its application |
| CN1939919A (en) * | 2005-09-30 | 2007-04-04 | 中国科学院福建物质结构研究所 | Low-toxic and broad-spectrum phthalocyanine bactericide, its production and use |
| CN101175512A (en) * | 2005-05-13 | 2008-05-07 | 株式会社奈特克 | Medical composition for promotion of skin regeneration |
| CN101879795A (en) * | 2010-06-08 | 2010-11-10 | 黑龙江大学 | Phthalocyanine/TiO2 ordered film and preparation method thereof |
| WO2012039887A1 (en) * | 2010-09-21 | 2012-03-29 | Bausch & Lomb Incorporated | Composition and method for promoting wound healing |
| KR20120072063A (en) * | 2010-12-23 | 2012-07-03 | 한국원자력연구원 | Hydrogels for wound or ulcer dressings comprising enzymes and preparation method thereof |
| CN102847193A (en) * | 2012-07-04 | 2013-01-02 | 杭州科洛生物技术有限公司 | Chitosan fluid dressing film |
| CN105381500A (en) * | 2015-11-23 | 2016-03-09 | 华中师范大学 | Functional wound surface repairing material and preparation method thereof |
| CN105622682A (en) * | 2016-03-10 | 2016-06-01 | 福州大学 | Zinc(II) carboxyl phthalocyanine and adriamycin conjugate and preparation and application thereof |
| CN105999358A (en) * | 2016-07-20 | 2016-10-12 | 广东泰宝医疗科技股份有限公司 | Method for preparing slow-release antibacterial dressing |
| CN106039394A (en) * | 2016-06-02 | 2016-10-26 | 四川奎星医用高分子制品有限责任公司 | Medical composite chitosan gel containing antibacterial drug |
| CN106620695A (en) * | 2016-08-30 | 2017-05-10 | 郑州嘉泰生物科技有限公司 | Photosensitive pharmaceutical preparation for photodynamic sterilization and application thereof |
-
2018
- 2018-05-09 CN CN201810439740.3A patent/CN108498855B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001029384A (en) * | 1999-05-20 | 2001-02-06 | Kao Corp | Absorptive article |
| WO2002090361A1 (en) * | 2001-03-21 | 2002-11-14 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| CN1593424A (en) * | 2004-07-15 | 2005-03-16 | 福州大学 | Novel method for preparing anticancer photosensitizer of amphiphilic phthalocyanine and its application |
| CN101175512A (en) * | 2005-05-13 | 2008-05-07 | 株式会社奈特克 | Medical composition for promotion of skin regeneration |
| CN1939919A (en) * | 2005-09-30 | 2007-04-04 | 中国科学院福建物质结构研究所 | Low-toxic and broad-spectrum phthalocyanine bactericide, its production and use |
| CN101879795A (en) * | 2010-06-08 | 2010-11-10 | 黑龙江大学 | Phthalocyanine/TiO2 ordered film and preparation method thereof |
| WO2012039887A1 (en) * | 2010-09-21 | 2012-03-29 | Bausch & Lomb Incorporated | Composition and method for promoting wound healing |
| KR20120072063A (en) * | 2010-12-23 | 2012-07-03 | 한국원자력연구원 | Hydrogels for wound or ulcer dressings comprising enzymes and preparation method thereof |
| CN102847193A (en) * | 2012-07-04 | 2013-01-02 | 杭州科洛生物技术有限公司 | Chitosan fluid dressing film |
| CN105381500A (en) * | 2015-11-23 | 2016-03-09 | 华中师范大学 | Functional wound surface repairing material and preparation method thereof |
| CN105622682A (en) * | 2016-03-10 | 2016-06-01 | 福州大学 | Zinc(II) carboxyl phthalocyanine and adriamycin conjugate and preparation and application thereof |
| CN106039394A (en) * | 2016-06-02 | 2016-10-26 | 四川奎星医用高分子制品有限责任公司 | Medical composite chitosan gel containing antibacterial drug |
| CN105999358A (en) * | 2016-07-20 | 2016-10-12 | 广东泰宝医疗科技股份有限公司 | Method for preparing slow-release antibacterial dressing |
| CN106620695A (en) * | 2016-08-30 | 2017-05-10 | 郑州嘉泰生物科技有限公司 | Photosensitive pharmaceutical preparation for photodynamic sterilization and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| CHEN, Z等: "Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy", 《ACTA BIOMATERIALIA》 * |
| HUANG, ZY: "Phthalocyanine-based coordination polymer nanoparticles for enhanced photodynamic therapy", 《NANOSCALE》 * |
| TANG, FX等: "Preparation and antifungal properties of monosubstituted zinc(II) phthalocyanine-chitosan oligosaccharide conjugates and their quaternized derivatives", 《DYES AND PIGMENTS》 * |
| 安鹏等: "携有邻苯二酚基团的新型酞菁锌的合成与表征", 《有机化学》 * |
| 柴凤兰等: "金属酞菁类化合物的应用研究进展", 《当代化工》 * |
| 段久芳: "《天然高分子材料》", 30 March 2016, 华中科技大学出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109680498A (en) * | 2019-01-11 | 2019-04-26 | 深圳市科能医疗器械有限公司 | A kind of medical preparation method for resisting antibacterial gauze of nanometer-level silver ion |
| CN111533827A (en) * | 2020-06-15 | 2020-08-14 | 北京化工大学 | Electronegative polysaccharide quaternary ammonium salt hemostatic material and preparation method and application thereof |
| CN111533827B (en) * | 2020-06-15 | 2021-04-02 | 北京化工大学 | Electronegative polysaccharide quaternary ammonium salt hemostatic material and preparation method and application thereof |
| CN113855844A (en) * | 2021-09-18 | 2021-12-31 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Antibacterial material and preparation method and application thereof |
| CN113855844B (en) * | 2021-09-18 | 2022-08-12 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Antibacterial material and preparation method and application thereof |
| CN115591008A (en) * | 2021-12-31 | 2023-01-13 | 上海炫鑫医药科技有限公司（Cn） | Spray-type liquid wound-protecting dressing and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108498855B (en) | 2021-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blaine | Experimental observations on absorbable alginate products in surgery: gel, film, gauze and foam | |
| CN101455857B (en) | Biocompatibility modified starch sponges | |
| CN101053669B (en) | Water soluble chitosan-based hemostatic wound-healing marine sponge and its preparation method and application | |
| CN108498855A (en) | A kind of antibacterial anti hemorrhagic colloidal sol and preparation method thereof | |
| JP2617260B2 (en) | Gel composition for wound treatment | |
| CN100348272C (en) | Method for preparing astringent sponge of soluble cellulose | |
| CN104623718B (en) | Chitosan petrolatum gauze and preparation method thereof | |
| CN101121041A (en) | Denaturated starch absorbable hemostatic material and preparation method thereof | |
| CN106620824B (en) | A kind of preparation method of high-efficiency antimicrobial compound hemostatic sponge | |
| CN102526795A (en) | Chitosan-based styptic sponge and preparation method thereof | |
| CN103848926B (en) | A kind of preparation method of using carboxyl chitosan and purposes | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| CN103083713A (en) | Sterile polymerized covering dressing for wound surface | |
| CN104857552B (en) | A kind of hemostatic adhesive bandage and preparation method thereof | |
| CN104906626A (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| CN105797203A (en) | Alginate fiber based collagen sponge dressing and preparation method thereof | |
| CN103755965A (en) | Epsilon-polylysine hydrogel and preparation method and application thereof | |
| JP2752782B2 (en) | Soluble hemostatic fabric | |
| CN101597381A (en) | A kind of calcium alginate composite membrane medical dressing of pasting behind the pin and its production and application that is used for | |
| CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
| CN102617884A (en) | Production method of medical biological material for human serum albumin | |
| CN104307031B (en) | A kind of Preparation method and use of external preparation for skin repair materials | |
| CN112295008A (en) | Bioactive dressing with anti-inflammatory and hemostatic functions | |
| CN106540310A (en) | A kind of absorbability rapid hemostatic material and preparation method thereof | |
| CN103174017B (en) | Sodium alginate oxide modified chitosan fiber and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |